Springworks Therapeutics Stock Price To Sales

SWTX Stock

USD 38.91 2.61 7.19%

SpringWorks Therapeutics fundamentals help investors to digest information that contributes to SpringWorks Therapeutics' financial success or failures. It also enables traders to predict the movement of SpringWorks Stock. The fundamental analysis module provides a way to measure SpringWorks Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SpringWorks Therapeutics stock.

		Last Reported	Projected for Next Year
	Price To Sales Ratio	422.99	444.14

Price To Sales Ratio is likely to rise to 444.14 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

SpringWorks Therapeutics Company Price To Sales Analysis

SpringWorks Therapeutics' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current SpringWorks Therapeutics Price To Sales

19.93 X

Most of SpringWorks Therapeutics' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SpringWorks Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

SpringWorks Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for SpringWorks Therapeutics is extremely important. It helps to project a fair market value of SpringWorks Stock properly, considering its historical fundamentals such as Price To Sales. Since SpringWorks Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of SpringWorks Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of SpringWorks Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Accounts Payable	Short Term Investments	Total Liab	Treasury Stock	Intangible Assets	Common Stock	Property Plant Equipment	Long Term Debt	Good Will	Net Tangible Assets	Net Debt	Retained Earnings	Net Invested Capital	Total Current Assets	Net Working Capital	Capital Surpluse	Deferred Long Term Liab	Capital Stock	Current Deferred Revenue	Short Term Debt
Total Assets		0.53	0.43	0.12	0.69	0.64	0.31	0.65	0.28	-0.19	-0.64	0.94	-0.68	-0.89	0.96	0.95	0.94	0.96	0.93	-0.94	0.93	0.83
Total Stockholder Equity	0.53		0.09	-0.31	0.28	0.6	0.25	0.45	0.0	-0.13	-0.6	0.45	-0.63	-0.43	0.47	0.38	0.37	0.57	0.54	-0.53	0.47	0.71
Accounts Payable	0.43	0.09		-0.64	0.67	0.34	-0.65	0.68	0.98	0.76	-0.34	0.32	-0.17	-0.46	0.33	0.33	0.32	0.33	0.32	-0.31	0.35	0.21
Short Term Investments	0.12	-0.31	-0.64		-0.17	-0.1	0.79	-0.33	-0.7	-0.85	0.08	0.19	-0.06	-0.11	0.19	0.25	0.26	0.15	0.14	-0.17	0.12	-0.03
Total Liab	0.69	0.28	0.67	-0.17		0.73	0.01	0.79	0.58	0.15	-0.74	0.5	-0.3	-0.84	0.52	0.52	0.49	0.54	0.51	-0.48	0.61	0.42
Treasury Stock	0.64	0.6	0.34	-0.1	0.73		0.31	0.59	0.25	-0.15	-0.8	0.53	-0.4	-0.84	0.54	0.45	0.41	0.54	0.59	-0.46	0.6	0.5
Intangible Assets	0.31	0.25	-0.65	0.79	0.01	0.31		-0.07	-0.76	-0.98	-0.34	0.3	-0.28	-0.36	0.31	0.31	0.3	0.34	0.32	-0.32	0.31	0.28
Common Stock	0.65	0.45	0.68	-0.33	0.79	0.59	-0.07		0.6	0.25	-0.88	0.37	-0.32	-0.74	0.41	0.41	0.39	0.53	0.38	-0.46	0.49	0.44
Property Plant Equipment	0.28	0.0	0.98	-0.7	0.58	0.25	-0.76	0.6		0.85	-0.23	0.19	-0.01	-0.32	0.19	0.19	0.18	0.17	0.17	-0.15	0.23	0.11
Long Term Debt	-0.19	-0.13	0.76	-0.85	0.15	-0.15	-0.98	0.25	0.85		0.15	-0.23	0.21	0.21	-0.23	-0.24	-0.23	-0.25	-0.24	0.24	-0.21	-0.2
Good Will	-0.64	-0.6	-0.34	0.08	-0.74	-0.8	-0.34	-0.88	-0.23	0.15		-0.38	0.41	0.81	-0.42	-0.38	-0.36	-0.54	-0.43	0.45	-0.49	-0.46
Net Tangible Assets	0.94	0.45	0.32	0.19	0.5	0.53	0.3	0.37	0.19	-0.23	-0.38		-0.67	-0.76	1.0	0.99	0.98	0.94	0.98	-0.95	0.93	0.83
Net Debt	-0.68	-0.63	-0.17	-0.06	-0.3	-0.4	-0.28	-0.32	-0.01	0.21	0.41	-0.67		0.48	-0.68	-0.67	-0.68	-0.81	-0.78	0.81	-0.44	-0.47
Retained Earnings	-0.89	-0.43	-0.46	-0.11	-0.84	-0.84	-0.36	-0.74	-0.32	0.21	0.81	-0.76	0.48		-0.78	-0.75	-0.72	-0.79	-0.77	0.73	-0.83	-0.64
Net Invested Capital	0.96	0.47	0.33	0.19	0.52	0.54	0.31	0.41	0.19	-0.23	-0.42	1.0	-0.68	-0.78		0.99	0.98	0.96	0.98	-0.96	0.94	0.84
Total Current Assets	0.95	0.38	0.33	0.25	0.52	0.45	0.31	0.41	0.19	-0.24	-0.38	0.99	-0.67	-0.75	0.99		1.0	0.95	0.95	-0.96	0.91	0.79
Net Working Capital	0.94	0.37	0.32	0.26	0.49	0.41	0.3	0.39	0.18	-0.23	-0.36	0.98	-0.68	-0.72	0.98	1.0		0.95	0.94	-0.96	0.9	0.79
Capital Surpluse	0.96	0.57	0.33	0.15	0.54	0.54	0.34	0.53	0.17	-0.25	-0.54	0.94	-0.81	-0.79	0.96	0.95	0.95		0.96	-0.99	0.87	0.8
Deferred Long Term Liab	0.93	0.54	0.32	0.14	0.51	0.59	0.32	0.38	0.17	-0.24	-0.43	0.98	-0.78	-0.77	0.98	0.95	0.94	0.96		-0.96	0.88	0.79
Capital Stock	-0.94	-0.53	-0.31	-0.17	-0.48	-0.46	-0.32	-0.46	-0.15	0.24	0.45	-0.95	0.81	0.73	-0.96	-0.96	-0.96	-0.99	-0.96		-0.85	-0.79
Current Deferred Revenue	0.93	0.47	0.35	0.12	0.61	0.6	0.31	0.49	0.23	-0.21	-0.49	0.93	-0.44	-0.83	0.94	0.91	0.9	0.87	0.88	-0.85		0.91
Short Term Debt	0.83	0.71	0.21	-0.03	0.42	0.5	0.28	0.44	0.11	-0.2	-0.46	0.83	-0.47	-0.64	0.84	0.79	0.79	0.8	0.79	-0.79	0.91

Click cells to compare fundamentals

SpringWorks Price To Sales Historical Pattern

Today, most investors in SpringWorks Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various SpringWorks Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of SpringWorks Therapeutics price to sales as a starting point in their analysis.

SpringWorks Therapeutics Price To Sales

Timeline

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict SpringWorks Therapeutics

Price To Sales Ratio Over Time

SpringWorks Price To Sales Ratio

Price To Sales Ratio

444.14

At this time, SpringWorks Therapeutics' Price To Sales Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, SpringWorks Therapeutics has a Price To Sales of 19.9298 times. This is 6.87% lower than that of the Biotechnology sector and 79.75% lower than that of the Health Care industry. The price to sales for all United States stocks is 74.52% lower than that of the firm.

SpringWorks Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SpringWorks Therapeutics' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SpringWorks Therapeutics could also be used in its relative valuation, which is a method of valuing SpringWorks Therapeutics by comparing valuation metrics of similar companies.

SpringWorks Therapeutics is currently under evaluation in price to sales category among its peers.

SpringWorks Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of SpringWorks Therapeutics from analyzing SpringWorks Therapeutics' financial statements. These drivers represent accounts that assess SpringWorks Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of SpringWorks Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	1.7B	3.1B	3.0B	1.4B	1.2B	1.4B
Enterprise Value	1.3B	3.0B	2.9B	1.3B	1.2B	1.3B

SpringWorks Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, SpringWorks Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to SpringWorks Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

SpringWorks Fundamentals

	Return On Equity	-0.59
	Return On Asset	-0.34
	Profit Margin	(2.03) %
	Operating Margin	(1.18) %
	Current Valuation	2.42 B
	Shares Outstanding	74.39 M
	Shares Owned By Insiders	2.01 %
	Shares Owned By Institutions	97.99 %
	Number Of Shares Shorted	11.63 M
	Price To Earning	6.14 X
	Price To Book	5.23 X
	Price To Sales	19.93 X
	Revenue	5.45 M
	Gross Profit	35 M
	EBITDA	(341.35 M)
	Net Income	(325.1 M)
	Cash And Equivalents	334.54 M
	Cash Per Share	6.81 X
	Total Debt	7.06 M
	Debt To Equity	0.02 %
	Current Ratio	9.80 X
	Book Value Per Share	7.17 X
	Cash Flow From Operations	(222.79 M)
	Short Ratio	13.14 X
	Earnings Per Share	(3.89) X
	Target Price	67.33
	Number Of Employees	305
	Beta	0.79
	Market Capitalization	2.7 B
	Total Asset	725.79 M
	Retained Earnings	(895.03 M)
	Working Capital	422.74 M
	Current Asset	29.13 M
	Current Liabilities	10.16 M
	Net Asset	725.79 M

About SpringWorks Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze SpringWorks Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SpringWorks Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SpringWorks Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for SpringWorks Stock Analysis

When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC